Giese

Giese (Roger W. Giese)

Company overview. The entry in the litigation database refers not to a company but to an individual: Roger W. Giese, PhD, a professor of pharmaceutical sciences at Northeastern University's Bouvé College of Health Sciences in Boston, Massachusetts. He held a Northeastern faculty appointment from 1973 to 2016 and directed its Environmental Cancer Research Program; he earned a PhD in organic chemistry at MIT. As a private individual, he has no ticker, no parent, no corporate ownership structure, and no reportable revenue or employee count.

Products / services / operations. Giese is an academic inventor, not a manufacturer or service provider. His research covered analytical biochemistry and bioanalytical mass spectrometry — the avidin-biotin labeling/amplification system, mass tags, DNA adductomics, and mass-spectrometric detection of carcinogen-DNA adducts, much of it NIH/NCI/NIEHS-funded. The patents asserted in the tracked case are method claims, not products: U.S. 4,478,914 and Re. 31,712 (applying multiple layers of a protein and ligand extender to a surface, issued 1984; reexamination certificate B1 issued June 17, 1997), with related avidin-biotin layering patents such as U.S. 4,282,287 and 4,656,252. His CV notes that caproylamidobiotin-NHS was licensed to several reagent companies.

Patent-litigation posture. One tracked case, entirely as plaintiff (1 plaintiff, 0 defendant appearances). This is a lone inventor asserting method patents against a reagent manufacturer and distributor — not an operating company defending against NPE suits, and not a corporate patent-assertion entity with an acquired portfolio. The suit was filed in the U.S. District Court for the District of Massachusetts, not a plaintiff-friendly Texas venue.

Notable case. Giese v. Pierce Chemical Co. (also naming Vector Laboratories), filed November 17, 1997 (D. Mass. Docket Nos. 97-12561-WGY, 97-12562-WGY), alleged contributory infringement and inducement arising from sales of avidin-biotin (ABC) detection kits. Judge William G. Young's opinions, 29 F. Supp. 2d 33 (D. Mass. 1998) and 43 F. Supp. 2d 98 (D. Mass. 1999), granted summary judgment on laches after a delay exceeding a decade, held most claims of the reexamined '914 patent invalid for impermissible enlargement during reexamination, and addressed the common-law experimental-use exception. The decisions are frequently cited on laches and experimental use.